News
Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...
U.S. pharmaceutical imports surged in March, exceeding $50 billion, as drugmakers stockpiled inventory in anticipation of ...
The S&P 500, the Dow Jones, and the NASDAQ all moved between 0.8% and 1% lower by mid-afternoon. Palantir (PLTR) stock ...
Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential tariffs on their products, which ...
The US merchandise-trade deficit with Ireland soared to a record in March on a massive inflow of pharmaceuticals and ...
WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for first quarter ...
Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrierData presented at Digestive Disease Week in San ...
During a live event, Daniel M. Geynisman, MD, and participants discussed which efficacy end points they value and how they ...
At this time, I would like to welcome everyone to the Jacobs fiscal second-quarter 2025 earnings conference call. (Operator Instructions) Thank you. And I would now like to turn the conference over to ...
We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this ...
Bluebird urged shareholders to back a take-private deal that could close imminently. Elsewhere, Unity Biotechnology began a strategic review and Mersana announced plans to cut more than half its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results